Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

11 results
Display

In response to: Steatotic liver disease-know your enemies

Le MH, Henry L, Nguyen MH

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study

Nguyen VH, Le I, Ha A, Le RH, Rouillard NA, Fong A, Gudapati S, Park JE, Maeda M, Barnett S, Cheung R, Nguyen MH

Background/Aims: Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nonalcoholic fatty liver disease and non-liver comorbidities

Manikat R, Nguyen MH

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by excess fat accumulation in the liver. It is closely associated with metabolic syndrome, and patients with NAFLD often...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

Ng CH, Huang DQ, Nguyen MH

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world’s adult population and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Le MH, Le DM, Baez TC, Dang H, Nguyen VH, Lee K, Stave CD, Ito T, Wu Y, Yeo YH, Ji F, Cheung R, Nguyen MH

Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events. Methods: We performed a systematic review...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH

Background/Aims: Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment

Oh H, Jun DW, Saeed WK, Nguyen MH

The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Screening of Endophytic Fungal Isolates Against Raffaelea quercus-mongolicae Causing Oak Wilt Disease in Korea

Nguyen MH, Yong JH, Sung HJ, Lee JK

Oak wilt disease caused by Raffaelea quercus-mongolicae has emerged obviously in Korea. We selected antifungal isolates against R. quercus-mongolicae among 368 endophytic fungal isolates from different parts of oak and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Fungal Community Analyses of Endophytic Fungi from Two Oak Species, Quercus mongolica and Quercus serrata, in Korea

Nguyen MH, Shin KC, Lee JK

Fungal endophytes have been recorded in various plant species with a richness of diversity, and their presence plays an essential role in host plant protection against biotic and abiotic stresses....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H, Cheung RC, Nguyen MH

BACKGROUND/AIMS: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, Fang YJ, Yang TH, Nguyen MH, Lin JT, Hsu YC

Background/Aims: Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr